Global Infectious Diseases Partnering 2014 to 2019 provides the
full collection of Infectious Diseases disease deals signed between the
world's pharmaceutical and biotechnology companies since 2014.
Trends in Infectious Diseases partnering deals
Financial deal terms for headline, upfront and royalty by stage of
development
Most of the deals included within the report occur when a licensee
obtains a right or an option right to license a licensors product or
technology. More often these days these deals tend to be multi-component
including both a collaborative R&D and a commercialization of outcomes
element.
The report takes readers through the comprehensive Infectious Diseases
disease deal trends, key players and top deal values allowing the
understanding of how, why and under what terms companies are currently
entering Infectious Diseases deals.
The report presents financial deal terms values for Infectious Diseases
deals, where available listing by overall headline values, upfront
payments, milestones and royalties enabling readers to analyse and
benchmark the value of current deals.
The initial chapters of this report provide an orientation of
Infectious Diseases dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Infectious Diseases
dealmaking since 2014 covering trends by year, deal type, stage of
development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering
headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Infectious Diseases deals
since 2014. Deals are listed by headline value. The chapter includes
the top 25 most active Infectious Diseases dealmakers, together with a
full listing of deals to which they are a party. Where the deal has an
agreement contract published at the SEC a link provides online access
to the contract.
Chapter 5 provides comprehensive access to Infectious Diseases deals
since 2014 where a deal contract is available, providing the user with
direct access to contracts as filed with the SEC regulatory
authorities. Each deal title links via Weblink to an online version of
the deal record contract document, providing easy access to each
contract document on demand.
Chapter 6 provides a comprehensive directory of all Infectious
Diseases partnering deals by specific Infectious Diseases target
announced since 2014. The chapter is organized by specific Infectious
Diseases therapeutic target. Each deal title links via Weblink to an
online version of the deal record and where available, the contract
document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of
all Infectious Diseases partnering deals signed and announced since
2014. The appendices are organized by company A-Z, stage of development
at signing, deal type (collaborative R&D, co-promotion, licensing etc)
and technology type. Each deal title links via Weblink to an online
version of the deal record and where available, the contract document,
providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the
trends and activities in Infectious Diseases partnering and dealmaking
since 2014.
In conclusion, this report provides everything a prospective dealmaker
needs to know about partnering in the research, development and
commercialization of Infectious Diseases technologies and products.
Report Scope
Global Infectious Diseases Partnering 2014 to 2019 is intended to
provide the reader with an in-depth understanding and access to
Infectious Diseases trends and structure of deals entered into by
leading companies worldwide.
Global Infectious Diseases Partnering 2014 to 2019 includes:
Trends in Infectious Diseases dealmaking in the biopharma industry
since 2014
Analysis of Infectious Diseases deal structure
Access to headline, upfront, milestone and royalty data
Access to hundreds of Infectious Diseases deal contract documents
Comprehensive access to over 1100 Infectious Diseases deal records
The leading Infectious Diseases deals by value since 2014
Most active Infectious Diseases dealmakers since 2014
The report includes deals for the following indications:
Bacterial: Anthrax, Campylobacter Jejuni, Clostridium difficile,
Diphtheria, Escherichia Coli (E-coli), Group A Streptococcus, Group B
Streptococcus, Haemophilus influenzae type b (Hib), Helicobacter
Pylori, Lyme disease, Methicillin-resistant Staphylococcus aureus
(MRSA), Mycobacterium avium, Pertussis (Whooping Cough), Pseudomonas
aeruginosa, Salmonella, Sepsis, Tetanus, Tuberculosis (TB), plus other
bacterial indications
Viral: Common cold, Cytomegalovirus, Ebola, FIV, Foot and mouth
disease, Hepatitis A, B, C, D, Herpes simplex, HIV, Influenza, H5N1
(Avian Flu), H1N1 (Swine Flu), Japanese encephalitis, Polio,
Respiratory syncytial virus (RSV), Zika, plus other viral indications.
Parasitic
Fungal: Nail Psoriasis, Onychomycosis (Nail infection), plus other
fungal indications
Tropical: African trypanosomiasis (Sleeping sickness), Dengue fever,
Malaria, West Nile Virus, Yellow fever, plus other tropical indications
The Global Infectious Diseases Partnering 2014-2019 report
provides comprehensive access to available deals and contract documents
for over 1,100 infectious diseases deals. Analyzing actual contract
agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are the sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or
deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
The "Europe
Welding Equipment Market-Growth, Trends, and Forecast (2019 - 2024)"
report has been added to ResearchAndMarkets.com's
offering.
Welding is one of the critical processes employed in the manufacturing...
Inovio Pharmaceuticals, Inc. announced today that its Ebola vaccine, INO-4201, was safe, tolerable, and generated strong T cell and antibody responses. This Phase 1 data was published in The Journal of Infectious Diseases and further supports the...
Merck , known as MSD outside the United States and Canada, and
NGM Biopharmaceuticals, Inc. (NGM) today announced that Merck has
exercised its option to extend the research phase of the companies'
broad, strategic collaboration...
The shareholders in Sandvik Aktiebolag are convened to the Annual General Meeting to be held on Monday, 29 April 2019 at 3:00 p.m. at the Göransson Arena, Sätragatan 21, Sandviken, Sweden.
RIGHT TO PARTICIPATE AND NOTICE
Shareholders who wish to...
The Oslo Business for Peace Award is given to inspiring business
leaders who have put society first.
2019's winners are: Dr Agbor Ashumanyi Ako,
medical director of GiftedMom, Alice Laugher, CEO of
Committed to...
The evolving competitive market has made it essential for the telecommunication industry to rethink traditional ways of doing business in terms of the impact on business models, service portfolios and technical architectures. Digital business support...